SIRT3 and breast carcinoma: In the present study, the inhibition of Sirt3 by luteolin or brusatol suggested that luteolin suppressed Sirt3 expression in breast cancer cells to attenuate stress adaptation and chemoresistance by reducing the expression of antioxidant enzymes.